- Home
- SSSS vs DERM Comparison
SSSS vs DERM Comparison
Compare SSSS & DERM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SSSS
- DERM
- Stock Information
- Founded
- SSSS 2010
- DERM 2014
- Country
- SSSS United States
- DERM United States
- Employees
- SSSS N/A
- DERM N/A
- Industry
- SSSS Finance: Consumer Services
- DERM Biotechnology: Pharmaceutical Preparations
- Sector
- SSSS Finance
- DERM Health Care
- Exchange
- SSSS Nasdaq
- DERM Nasdaq
- Market Cap
- SSSS 227.8M
- DERM 213.6M
- IPO Year
- SSSS N/A
- DERM 2021
- Fundamental
- Price
- SSSS $10.11
- DERM $9.17
- Analyst Decision
- SSSS Strong Buy
- DERM Strong Buy
- Analyst Count
- SSSS 4
- DERM 3
- Target Price
- SSSS $10.13
- DERM $12.67
- AVG Volume (30 Days)
- SSSS 255.7K
- DERM 187.7K
- Earning Date
- SSSS 11-04-2025
- DERM 11-12-2025
- Dividend Yield
- SSSS 9.99%
- DERM N/A
- EPS Growth
- SSSS N/A
- DERM N/A
- EPS
- SSSS 2.60
- DERM N/A
- Revenue
- SSSS $2,354,933.00
- DERM $56,397,000.00
- Revenue This Year
- SSSS $7,183.09
- DERM $26.16
- Revenue Next Year
- SSSS N/A
- DERM $45.27
- P/E Ratio
- SSSS $3.84
- DERM N/A
- Revenue Growth
- SSSS N/A
- DERM N/A
- 52 Week Low
- SSSS $4.21
- DERM $3.54
- 52 Week High
- SSSS $10.34
- DERM $9.30
- Technical
- Relative Strength Index (RSI)
- SSSS 63.88
- DERM 70.61
- Support Level
- SSSS $9.68
- DERM $7.67
- Resistance Level
- SSSS $10.23
- DERM $9.30
- Average True Range (ATR)
- SSSS 0.34
- DERM 0.47
- MACD
- SSSS 0.09
- DERM 0.14
- Stochastic Oscillator
- SSSS 82.45
- DERM 87.56
About SSSS SuRo Capital Corp.
SuRo Capital Corp is a non-diversified closed-end management investment company. The company's investment objective is to maximize its portfolio's total return, principally by seeking capital gains on its equity and equity-related investments.
About DERM Journey Medical Corporation
Journey Medical Corp is a commercial stage pharmaceutical company focused on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions. The company's current product portfolio includes eight FDA-approved prescription drugs for dermatological conditions that are marketed in the U.S. Some of the group's products are Qbrexza, Accutane, Amzeeq, Exelderm and others.